Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie is conducting a study titled ‘A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression.’ The study aims to evaluate the safety and efficacy of Mirvetuximab Soravtansine, an investigational drug targeting cancer cells with high folate receptor-alpha expression, in patients with platinum-resistant ovarian cancer.
The intervention being tested is Mirvetuximab Soravtansine, an antibody-drug conjugate administered intravenously. It is designed to selectively target and kill cancer cells by delivering a cytotoxic agent to cells expressing folate receptor-alpha.
The study is interventional, with a randomized, parallel assignment model and no masking. Its primary purpose is treatment, focusing on optimizing dosing schedules for Mirvetuximab Soravtansine in different patient cohorts.
The study began on May 28, 2025, with an estimated completion timeline of 24 months. The last update was submitted on July 14, 2025, indicating ongoing recruitment and progress.
This study update could influence AbbVie’s stock performance positively, as successful results may enhance their oncology portfolio. Investors should watch for developments, especially in comparison to competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.